Sarepta Names Severino CEO in Planned Succession

Company Sarepta Therapeutics Event Type Leadership Transition (CEO Appointment / Planned Succession) Modality AAV gene therapy, exon-skipping PMO medicines, and emerging siRNA platform Platform ELEVIDYS (AAVrh74-delivered micro-dystrophin gene therapy) and PMO Duchenne portfolio, plus ligand-directed siRNA pipeline Indication Duchenne muscular dystrophy (primary); pipeline includes FSHD1,…